Fig. 1 · Structure

Documents & Downloads

Dexamethasone

Cat. No. A10299 CAS 50-02-2

glucocorticoid receptor agonist

Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs. It acts as an anti-inflammatory and immunosuppressant. Its potency is about 20-30 times that of the naturally occurring hormone hydrocortisone and 4-5 times of prednisone.

In Stock

Publications for Dexamethasone

4 publications citing this product

  1. Sudam S Mane, .et al. , J Am Soc Mass Spectrom, 2025, Nov 5;36(11):2480-2488 PMID: 41115840
  2. Sudam S Mane, .et al. , J Am Soc Mass Spectrom, 2024, Aug 26 PMID: 39186802
  3. Ken Kobayashi, .et al. , Cell Tissue Res, 2022, Sep;389(3):501-515 PMID: 35748981
  4. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Dexamethasone activated a GR-responsive transcriptional reporter in A549 cells (EC50 34 nM). Antagonist displacement and GR knockdown supported receptor involvement; this cellular EC50 is not a binding affinity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 15 μM Anticancer against human A549 cells after 72 hrs by MTT assay [PMID: 24992071]
A549 EC50 1 nM Activity at glucocorticoid receptor in human A549 cells assessed as effect on GRE promoter response by luciferase reporter assay [PMID: 16643060]
A549 EC50 1.1 nM Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of IL-1-beta-induced NF-kappaB dependent E-selection promoter activation after 6 hrs by luciferase reporter gene based ELAM assay [PMID: 20047280]
A549 EC50 1.1 nM Agonist activity at glucocorticoid receptor in human A549 cells assessed as E-selectin transrepression by luciferase reporter gene assay [PMID: 24980053]
A549 EC50 1.1 nM Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL-1beta-induced NF-kappaB dependent E-selectin activation by luciferase reporter gene assay [PMID: 23953070]
A549 EC50 1.1 nM Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay [PMID: 23916594]
A549 EC50 1.1 nM Transrepression activity of glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay [PMID: 21073190]
A549 EC50 1.1 nM Transrepression activity at GR in IL-1-beta-stimulated human A549 cells assessed as inhibition of NF-kappaB-dependent E-selectin transcription by luciferase reporter gene assay [PMID: 19321341]
A549 EC50 2.5 nM Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of PMA-induced AP1 activity after 6 hrs by luciferase reporter gene assay [PMID: 20047280]
A549 EC50 2.5 nM Agonist activity at glucocorticoid receptor in human A549 cells assessed as AP-1 transrepression by luciferase reporter gene assay [PMID: 24980053]
A549 EC50 2.5 nM Transrepression of glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay [PMID: 24011644]
A549 EC50 2.5 nM Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activation by luciferase reporter gene assay [PMID: 23953070]
A549 EC50 2.5 nM Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-stimulated AP1 response element by luciferase reporter gene assay [PMID: 23916594]
A549 EC50 2.5 nM Transrepression activity of glucocorticoid receptor in human A549 cells expressing AP-1 assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay [PMID: 21073190]
B16-F10 IC50 > 20 μM Anticancer against mouse B16F10 cells after 72 hrs by MTT assay [PMID: 24992071]
B-cell IC50 0.8 μM Immunosuppressive activity against BALB/C mouse B lymphocytes assessed as reduction in LPS-induced cell proliferation by measuring [3H]-thymidine uptake incubated for 8 hrs by Beta scintillation counting method [PMID: 31961677]
BV-2 IC50 2.5 x 10 Antiinflammatory activity in C57BL6/J mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay [PMID: 26110443]
CHO IC50 > 20 μM Cytotoxicity against CHO cells after 72 hrs by MTT assay [PMID: 24992071]
COS-7 EC50 7.2 nM Agonist activity at glucocorticoid receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay [PMID: 19863083]

19 records · Scroll to view more

Dexamethasone Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Dexamethasone from 2 published references. In vitro models include IL-1β-stimulated human A549 cells.

Dexamethasone In Vitro Studies

In IL-1β-stimulated A549 cells, 1 µM dexamethasone repressed 34 of 39 tested transcripts after 6 h. BIRC3, CSF3, IL32, SOD2 and TNFAIP3 were not repressed. Repression potency depended on the transcript: reported EC50 values were 0.75 nM for IL1B and 170 nM for CFB. [1]

GR-dependent transcriptional reporter response

Cell-based study · Human pulmonary A549 cells stably expressing a 2×GRE luciferase reporter [1]

Dexamethasone increased reporter activity; antagonist displacement and GR-specific siRNA supported GR dependence. The EC50 is a cellular transcription endpoint.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Dexamethasone-induced 2×GRE luciferase activityEC50 34 nM[1]
Reporter response with GR antagonism or knockdownQualitative control result ORG34517 caused rightward parallel concentration-response displacement; GR siRNA strongly attenuated reporter activity, whereas lamin siRNA did not.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration–response series; 1 µM dexamethasone reference response
Exposure duration
6 h dexamethasone exposure
Method
Luciferase assay; ORG34517 pretreatment or GR/lamin siRNA controls
Vehicle
Dexamethasone dissolved in HBSS; ORG34517 in DMSO (final DMSO <0.1%)
Co-treatment
ORG34517: 30 min pretreatment; GR or lamin control siRNA: 24 h before dexamethasone
Reported limits
Sigma catalogue number, chemical purity and explicit salt/ester form not specified.
Methods and source locations

Compound reported in the paper: Dexamethasone; Compound label in the paper: Dex

Published compound-level evidence; tested supplier material differs from Adooq A10299. No lot equivalence or salt conversion is established.

Figure 3A–C, caption and Results: Repression of IL-1β-induced Gene Expression by Dexamethasone is Dependent on GR

Dexamethasone-induced 2×GRE luciferase activity: Luciferase; n=4–5, means ± SE in Figure 3A — Figure 3A and accompanying GR-dependence Results

Reporter response with GR antagonism or knockdown: Luciferase; Figure 3A,C n=4–5, means ± SE; Figure 3B immunoblot controls n=5 — Figure 3A–C and accompanying text

Gene-specific repression of inflammatory transcripts

Cell-based study · IL-1β-stimulated human A549 cells [1]

Repression varied by transcript; five of 39 transcripts were not repressed. GR antagonism and GR knockdown supported receptor involvement without establishing a single universal repression mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL-1β-induced transcript expressionSignificantly repressed transcripts 34 of 39; BIRC3, CSF3, IL32, SOD2 and TNFAIP3 were not repressed.[1]
Repression of IL1B and CFB mRNAEC50 IL1B: 0.75 nM; CFB: 170 nM[1]
Reversal of dexamethasone-dependent transcript repressionSignificant reversal ORG34517: 32/34 transcripts; GR siRNA: 33/34 at 0.1 and/or 1 µM dexamethasone.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Dexamethasone 1 µM for the 39-transcript comparison; concentration–response series for EC50; 0.1 or 1 µM in GR validation
Exposure duration
6 h
Method
Real-time PCR, GAPDH normalization
Vehicle
Dexamethasone in HBSS; ORG34517 in DMSO (final DMSO <0.1%)
Co-treatment
IL-1β 1 ng/ml; ORG34517 1 µM 30 min before stimulation, or GR/lamin siRNA 24 h before stimulation
Reported limits
Full concentration-series point list not transcribed; no independent protein-level confirmation is assigned to these transcript outcomes.
Methods and source locations

Compound reported in the paper: Dexamethasone; Compound label in the paper: Dex

Published compound-level evidence; tested supplier material differs from Adooq A10299. No lot equivalence or salt conversion is established.

Figure 2A,C; Figure 3D; Results: effects of concentration and GR dependence

IL-1β-induced transcript expression: Real-time PCR; Figure 2A combined n=9, means ± SE; non-parametric paired t-test as described in caption — Figure 2A and Results: Effect of IL-1β and Dexamethasone on Inflammatory Gene Expression

Repression of IL1B and CFB mRNA: Concentration–response real-time PCR; exact values from Results text, not curve estimation — Figure 2C and Results: Effect of Dexamethasone Concentration on IL-1β-induced Gene Expression

Reversal of dexamethasone-dependent transcript repression: Real-time PCR; Figure 3D n=5–6, means ± SE; lamin siRNA control — Figure 3D and GR-dependence Results

Dexamethasone In Vivo Studies

In male C57BL/6J mice, a 10-day intraperitoneal dexamethasone regimen (25 mg/kg) reduced running endurance and grip strength relative to saline controls. Trimetazidine co-treatment attenuated the functional impairment. These results describe an adverse-effect model, not therapeutic efficacy. [2]

Exercise and grip impairment in dexamethasone-treated mice

Animal study · 8-week-old male C57BL/6J mice; randomized saline, DEX, trimetazidine and combination groups (n=8/group) [2]

DEX impaired exercise endurance and grip strength. Trimetazidine co-treatment attenuated these effects; this is a combination comparison, not an intrinsic beneficial effect of DEX.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Treadmill running distance to exhaustionMean ± SEM DEX: 181.94 ± 14.94 m; control: 337.71 ± 41.98 m; DEX + TMZ: 273.00 ± 16.88 m[2]
Treadmill running time to exhaustionMean ± SEM DEX: 13.48 ± 0.94 min; control: 21.03 ± 2.28 min; DEX + TMZ: 16.84 ± 1.09 min[2]
Forelimb grip strengthMean ± SEM DEX: 90 ± 3.79 g; DEX + TMZ: 114.25 ± 5.25 g[2]

Conditions shared by the study groups

Route
Intraperitoneal
Treatment course
10 days
Vehicle
0.9% saline control; dosing vehicle for active compounds not specified in Mice subsection
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saline controlControl armRunning distance 337.71 ± 41.98 m; running time 21.03 ± 2.28 min.[2]
Dexamethasone alone
25 mg/kg
0.9% saline control groupRunning distance 181.94 ± 14.94 m; running time 13.48 ± 0.94 min; grip strength 90 ± 3.79 g.[2]
Dexamethasone plus trimetazidine
Dexamethasone 25 mg/kg + trimetazidine 5 mg/kg
0.9% saline control groupRunning distance 273.00 ± 16.88 m; running time 16.84 ± 1.09 min; grip strength 114.25 ± 5.25 g.[2]
Saline control
Model: 8-week-old male C57BL/6J mice
Reported limits: Injection frequency is not explicitly stated in the Mice subsection; no frequency inferred from body-weight sampling.
Dexamethasone alone
Model: 8-week-old male C57BL/6J mice
Reported limits: Injection frequency is not explicitly stated in the Mice subsection; no frequency inferred from body-weight sampling.
Dexamethasone plus trimetazidine
Model: 8-week-old male C57BL/6J mice
Reported limits: Injection frequency is not explicitly stated in the Mice subsection; no frequency inferred from body-weight sampling.
Methods and source locations

Compound reported in the paper: Dexamethasone; Compound label in the paper: DEX

Published compound-level evidence; tested supplier material differs from Adooq A10299. No lot equivalence or salt conversion is established.

Materials and methods: Mice, Running test, Grip strength test, Statistical analysis; Results mouse atrophy subsection; Figure 4B–C

Treadmill running distance to exhaustion: n=8/group; exact values in Results; Figure 4Ba visually checked — Figure 4Ba, caption and mouse atrophy Results

Treadmill running time to exhaustion: n=8/group; exact values in Results; Figure 4Bb visually checked — Figure 4Bb, caption and mouse atrophy Results

Forelimb grip strength: n=8/group; exact values in Results; no exact control value inferred from bars — Figure 4C, caption and mouse atrophy Results

Saline control · Mice; Figure 4B–C and caption; Results: Trimetazidine alleviates dexamethasone-induced muscle atrophy in mice

Dexamethasone alone · Mice; Figure 4B–C and caption; Results: Trimetazidine alleviates dexamethasone-induced muscle atrophy in mice

Dexamethasone plus trimetazidine · Mice; Figure 4B–C and caption; Results: Trimetazidine alleviates dexamethasone-induced muscle atrophy in mice

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 50-02-2
Applications

glucocorticoid receptor agonist

Formula C22H29FO5
Molecular Weight 392.5
Synonyms Decadron
SMILES
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 73 mg/mL (186 mM)
Water Insoluble
Ethanol 6 mg/mL (15.28 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
12 mg/mL
Vehicle
5% DMSO+45% PEG 300+H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Dexamethasone Research References

  1. [1] King EM, Chivers JE, Rider CF, et al. Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms PLoS One (2013). PMID: 23349769 DOI: 10.1371/journal.pone.0053936 Source material
  2. [2] Wang L, Jiao XF, Wu C, et al. Trimetazidine attenuates dexamethasone-induced muscle atrophy via inhibiting NLRP3/GSDMD pathway-mediated pyroptosis Cell Death Discov (2021). PMID: 34537816 DOI: 10.1038/s41420-021-00648-0 Source material

Publications

4 publications citing this product

  1. Sudam S Mane, .et al. , J Am Soc Mass Spectrom, 2025, Nov 5;36(11):2480-2488 PMID: 41115840
  2. Sudam S Mane, .et al. , J Am Soc Mass Spectrom, 2024, Aug 26 PMID: 39186802
  3. Ken Kobayashi, .et al. , Cell Tissue Res, 2022, Sep;389(3):501-515 PMID: 35748981
  4. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967

Added to your cart

View Cart Checkout
Loading...